VRCA · Verrica Pharmaceuticals Inc. · Webcasts, Transcripts & Audio
$3.56
-0.16 (-4.30%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Nov 13, 2026
Market Cap
$61.16M
Shares
17.18M
Volume · Nov 13
18.68K
Avg daily vol (3M)
72.22K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Verrica Pharmaceuticals Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Verrica Pharmaceuticals Inc. (VRCA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-12
Verrica Pharmaceuticals Inc. (VRCA) Q3 2026 Earnings Call Transcript
Confident tone
VP315 for Gorlin syndrome
Common warts Phase III program
Cash runway and financing
Revenue
$6.91M
▼ 51.8% YoY Diluted EPS
$-0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-06
Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
Confident tone
Common warts (COVID) Phase 3 program
International partnerships and launches
Pipeline asset VP315 in basal cell carcinoma
Revenue
$5.86M
▼ 53.8% YoY Diluted EPS
$-0.62
▼ 3200% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Confident tone
VP315 basal cell carcinoma program
Ycanth commercial momentum
Common warts Phase III (COV-2 / COV-3)
Revenue
$5.02M
▲ 46.1% YoY Diluted EPS
$-0.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-11
Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call
Revenue
$5.09M*
▲ 1380.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript
Positive tone
VP-315 basal cell carcinoma Phase III
YCANTH commercial growth and dispensed units
Global Phase III common warts with Torii
Revenue
$14.34M
Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript
Confident tone
YCANTH commercial growth
Pipeline expansion
Torii partnership and amended agreement
Revenue
$12.70M
▲ 145.4% YoY Diluted EPS
$0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Verrica Pharmaceuticals Inc. (VRCA) Q1 2025 Earnings Call
Revenue
$3.44M
▼ 10.1% YoY Diluted EPS
$-1.03
Gross margin
79.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Verrica Pharmaceuticals Inc. (VRCA) Q4 2024 Earnings Call Transcript
Positive tone
Pipeline Expansion - Common Warts and YCANTH Label Expansion
BP-315 / Basal Cell Carcinoma Program
Financial Position and Capital Raise
Revenue
$344,000*
▼ 82.7% YoY Gross margin
-132.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-08-14
Verrica Pharmaceuticals Inc. (VRCA) Q2 2024 Earnings Call Transcript
Confident tone
YCANTH commercial launch and revenue
VP-315 basal cell carcinoma Phase 2 results
Distribution and GPO partnerships
Revenue
$5.18M
▲ 2744.5% YoY Diluted EPS
$-3.70
Gross margin
86.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Verrica Pharmaceuticals Inc. (VRCA) Q1 2024 Earnings Call Transcript
Confident tone
YCANTH commercial launch and revenue growth
Regulatory milestones and exclusivity
Pipeline advancement (common warts and VP-315)
Revenue
$3.83M
▲ 10240.5% YoY Diluted EPS
$-4.40
Gross margin
81.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript
Confident tone
YCANTH Commercial Launch
Reimbursement and Coverage
Distribution Expansion
Revenue
$1.99M*
▲ 2823.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Verrica Pharmaceuticals Inc. (VRCA) Q3 2023 Earnings Call Transcript
Revenue
$2.92M
▼ 64.9% YoY Diluted EPS
$-5.40
Gross margin
89.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-14
Verrica Pharmaceuticals Inc. (VRCA) Q2 2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–13 of 13 webcasts
Key facts
CIK
1660334
CUSIP
92511W207
13F (30d)
46 filings
25 filers
Visit website
Investor relations